drugset / Trial / NCT02907294
Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 "After Multiple Oral Doses" in Healthy Volunteers
Phase 1
Terminated
8 enrolled
Palobiofarma SL
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
To assess the safety and tolerability of five doses of PBF-999 (160 mg and 320mg) after repeated (8 days) single daily oral dose administration in young male and female healthy subjects.
Timeline
- Start
- 2016-03
- Primary completion
- 2016-04
- Completion
- 2016-05
Outcome
Outcome not reported
Stopped: “change in the therapeutic indication”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PBF-999 | Small molecule | 160 mg | Oral |
| Subject | PBF-999 | Small molecule | 320 mg | Oral |